Commentary from a research paper published in the American Journal of Ophthalmology has cautioned clinicians to be both realistic and hopeful in their communications with… Read More »Journal paper advises caution among clinicians in communicating the potential benefits and timelines for ocular gene therapy
Research, led by scientists at the Kresge Eye Institute, Wayne State University, Michigan, has shown that mitochondrial DNA methylation is affected by high glucose levels… Read More »Hyper-methylation of mitochondrial DNA in diabetes may contribute to acceleration of cell death in the retina.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the September 6th, 2015 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »September 6th, 2015: “EURETINA-Brief”© Issue No. 116
Inherited retinal disorders (IRDs) are estimated to affect millions of individuals on a global scale, in many instances leading to significantly reduced vision or blindness.… Read More »Converting rods into cones in a model of retinitis pigmentosa (RP) rescues retinal degeneration.
Shire plc (LSE: SHP, NASDAQ: SHPG) has announced the acquisition of Foresight Biotechnologies Inc., based in New York for $300 million in an all-cash deal.… Read More »Shire Pharmaceuticals acquires Foresight Biotherapeutics Inc. to gain infectious conjunctivitis treatment entering Phase III
A Phase Ib/IIa clinical trial has reportedly treated the first macular edema patient with a novel delivery system designed to increase compliance and improve drug… Read More »Safety and efficacy of ocular iontophoresis with dexamethasone solution undergoes clinical testing with novel delivery system
Research, led by scientists at the Kyoto University Graduate School of Medicine, Japan, has demonstrated that the Genetic Risk Score (GRS), using five previously characterised… Read More »Genetic risk score on select genes provides predictive tool for second eye involvement in AMD
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the August 18th, 2015 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »August 18th, 2015: “EURETINA-Brief”© Issue No. 115
Applied Genetic Technologies Corp. (NASDAQ: AGTC) and Biogen Inc. (NASDAQ: BIIB) have announced a collaborative partnership to develop gene therapies for ophthalmic disease. According to… Read More »Applied Genetic Technologies Corp. (NASDAQ:AGTC) and Biogen Inc. (NASDAQ:BIIB) sign commercial agreement to develop gene therapies for ophthalmic disease
Phase II clinical trial data from a study of integrin peptide therapy (referenced as “ALG-1001” or “Luminate”), conducted in 106 patients with vitreomacular traction (VMT)… Read More »Phase II clinical trial data on novel integrin therapy for VMT indicates statistical improvement over placebo